GlaxoSmithKline has issued a recall of its antidepressant drug Paxil after receiving a US FDA Warning Letter for failing to fully investigate contamination issues at an Irish API plant.
Furiex posts Q2 loss as increased R&D spending and higher admin costs offset revenue gains, but firm is confident development model can boost partners’ pipelines.
Canadian drugmaker Labopharm says its Italian API maker Gruppo Angelini has resolved all the US FDA concerns about processes used to make a once-a day version of the depression drug trazodone.
Researchers have, for the first time, unearthed a genetic variation
that makes women more likely to suffer from the most extreme form
of premenstrual tension or syndrome (PMT, PMS).
Novartis is aiming to hunt down its rivals through a pipeline of
truly innovative drugs, measured by increasing numbers of New
Molecular Entities (NMEs) in development.
Transdermal drug delivery expert Noven Pharmaceuticals is to buy
JDS Pharmaceuticals in a deal worth $125m (€91m) to transform
itself into a 'fully-integrated speciality pharmaceutical company'.
DOV Pharmaceutical has announced the initiation of a Phase Ib
clinical trial, which investigates the potential of its triple
reuptake inhibitor candidate for treating depression. The drug's
mechanism of action inhibits three...
The first melatonergic antidepressant to offer a new approach to
the treatment of depression is just over the horizon after new data
demonstrated positive efficacy with marked improvements in sleep
with no effect on daytime vigilance.
A new class of antipressant - dubbed the triple reuptake inhibitor
- will in time come to dominate the market for depression
treatments and achieve multibillion dollar revenues, according to
new market research.
UK-headquartered pharma giant GlaxoSmithKline says it has overcome
the manufacturing problems that caused it to voluntarily withdraw
its antidepressant Paxil CR (paroxetine) and diabetes drug
Avandamet (metformin and rosiglitazone)...
A new type of antidepressant drug with a novel mechanism of action,
which acts on a new target, has entered Phase I clinical trials.
The drug could represent a new generation of psycho-active
compounds that are devoid of the problems...
A revolutionary new treatment for depression has been granted
marketing authorisation by the European Commission. The new therapy
is said to be able to treat the full spectrum of depressive
symptoms.
Worldwide efforts to produce a newer, safer antidepressant have
never been more imperative after a US landmark ruling requires all
antidepressant drugs to carry the strongest possible warning,
informing the public of the risks of...
A case currently going through the European Court of Justice could
have worrying implications for companies that use reformulation and
drug delivery as a way to extend the patented lifespan of their
drugs.
Researchers in the US have provided the first direct evidence in
mice for the role of an enzyme that specifically controls the
production of serotonin in the brain.
Italy's Abiogen Pharma has licensed rights to two UK-developed
compounds that seem to work via a completely new mechanism of
action for the treatment of anxiety.
The UK's Medicines and Healthcare products Regulatory Agency has
asked for prescribing restrictions on GlaxoSmithKline's
widely-prescribed antidepressant Seroxat.
